Prior art

Based on the provided patent text, only one US patent is explicitly cited as prior art: U.S. Pat. No. 6,172,213. Other references mentioned are non-patent literature.

Here is the information for the most relevant patent prior art:

U.S. Pat. No. 6,172,213

• Full Citation: US 6,172,213 B1, "Antibody binding IgE and humanized variants thereof", issued January 9, 2001.
• Publication/Filing Date: The filing date was November 24, 1998, and the publication (issue) date was January 9, 2001.
• Brief Description: This patent describes antibodies that bind to human immunoglobulin E (IgE) and humanized variants of these antibodies. It covers specific amino acid sequences for the heavy chain variable region (VH) and the light chain variable region (VL) of omalizumab (referred to as E25 in the patent), as well as the full-length heavy and light chains. The invention generally relates to antibodies that specifically bind IgE, methods of producing them, and their use in treating IgE-related disorders.
• Potential Claim(s) Anticipated under 35 U.S.C. § 102: Without access to the specific claims of US patent 12030959, it is not possible to definitively identify which claims, if any, are potentially anticipated by US 6,172,213. However, US 6,172,213 is foundational for omalizumab itself, describing the composition of the anti-IgE antibody. Therefore, any claims in US12030959 that describe omalizumab as a composition of matter, or its fundamental mechanism of binding IgE, would likely find strong prior art in US 6,172,213. US12030959 specifically refers to US 6,172,213 for the amino acid sequences of omalizumab, indicating that the antibody itself is described in this earlier patent. The novelty of US12030959 likely lies in the method of use (treating multiple food allergies) and specific dosing regimens for a particular patient population (e.g., young children with high IgE), rather than the antibody composition itself.